E-drug: Ingelfinger rule (cont)
---------------------------------------------
Hi, E-druggers
Thank you very much Blaine for your concrete and precise response
about the revised Ingelfinger rule. Anyway, in Japan, most of medias
convey news of medical research to their readers or audience as inside
reports or reputation as well as explanational reports on published
articles of another journal.
The Ingelfinger rule is NOT known in both Japanese medical journalists
and medical researchers. So many irrational therapies are performed
by not only non-medical workers but also MDs in Japan.
To the patients, most of them persuade their irrational therapies as such
"This therapy was introduced by that great newspaper" etc.
Of course, no negative information about it is presented to the patients.
Some cause malpractices into death. Some cause frauds and patients lose
their money very much. Irrational therapy threaten patients lives.
That's why I want to know about the Ingelfinger rule and I really want to
know the circumstances about flow of medical research information to the
patients by medias in another country, particularly in developing country.
Regards
Saio
Saio,Takeo MD.
Ando Hospital,Japan
72-1,Hanike Karausu-cho,Tsushima,496-0026,Japan
Tel;+81-567-31-4070 FAX;+81-567-32-1482
e-mail; saio@ppp.bekkoame.ne.jp
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.